|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Steeg PS: Tumor metastasis: Mechanistic
insights and clinical challenges. Nat Med. 12:895–904. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Byler S, Goldgar S, Heerboth S, Leary M,
Housman G, Moulton K and Sarkar S: Genetic and epigenetic aspects
of breast cancer progression and therapy. Anticancer Res.
34:1071–1077. 2014.PubMed/NCBI
|
|
5
|
Sun Y, Wang Y, Fan C, Gao P, Wang X, Wei G
and Wei J: Estrogen promotes stemness and invasiveness of
ER-positive breast cancer cells through Gli1 activation. Mol
Cancer. 13:1372014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Geng SQ, Alexandrou AT and Li JJ: Breast
cancer stem cells: Multiple capacities in tumor metastasis. Cancer
Lett. 349:1–7. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nijman SM, Luna-Vargas MP, Velds A,
Brummelkamp TR, Dirac AM, Sixma TK and Bernards R: A genomic and
functional inventory of deubiquitinating enzymes. Cell.
123:773–786. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fan YH, Yu Y, Mao RF, Tan XJ, Xu GF, Zhang
H, Lu XB, Fu SB and Yang J: USP4 targets TAK1 to downregulate
TNFα-induced NF-κB activation. Cell Death Differ. 18:1547–1560.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xiao N, Li H, Luo J, Wang R, Chen H, Chen
J and Wang P: Ubiquitin-specific protease 4 (USP4) targets TRAF2
and TRAF6 for deubiquitination and inhibits TNFα-induced cancer
cell migration. Biochem J. 441:979–986. 2012. View Article : Google Scholar
|
|
10
|
Zhou F, Zhang X, van Dam H, Ten Dijke P,
Huang H and Zhang L: Ubiquitin-specific protease 4 mitigates
Toll-like/interleukin-1 receptor signaling and regulates innate
immune activation. J Biol Chem. 287:11002–11010. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang X, Berger FG, Yang J and Lu X: USP4
inhibits p53 through deubiquitinating and stabilizing ARF-BP1. EMBO
J. 30:2177–2189. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang L, Zhou F, Drabsch Y, Gao R,
Snaar-Jagalska BE, Mickanin C, Huang H, Sheppard KA, Porter JA, Lu
CX, et al: USP4 is regulated by AKT phosphorylation and directly
deubiq-uitylates TGF-β type I receptor. Nat Cell Biol. 14:717–726.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Milojevic T, Reiterer V, Stefan E, Korkhov
VM, Dorostkar MM, Ducza E, Ogris E, Boehm S, Freissmuth M and
Nanoff C: The ubiquitin-specific protease Usp4 regulates the cell
surface level of the A2A receptor. Mol Pharmacol. 69:1083–1094.
2006. View Article : Google Scholar
|
|
14
|
Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang
P, He X, Wang Q, Huang Y, Jen KY, et al: CUL4A induces
epithelial-mesenchymal transition and promotes cancer metastasis by
regulating ZEB1 expression. Cancer Res. 74:520–531. 2014.
View Article : Google Scholar :
|
|
15
|
Yang HS, Matthews CP, Clair T, Wang Q,
Baker AR, Li CC, Tan TH and Colburn NH: Tumorigenesis suppressor
Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase
kinase 1expression to suppress colon carcinoma cell invasion. Mol
Cell Biol. 26:1297–1306. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen Z, Yuan YC, Wang Y, Liu Z, Chan HJ
and Chen S: Down-regulation of programmed cell death 4 (PDCD4) is
associated with aromatase inhibitor resistance and a poor prognosis
in estrogen receptor-positive breast cancer. Breast Cancer Res
Treat. 152:29–39. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Luo M, Brooks M and Wicha MS:
Epithelial-mesenchymal plasticity of breast cancer stem cells:
implications for metastasis and therapeutic resistance. Curr Pharm
Des. 21:1301–1310. 2015. View Article : Google Scholar :
|
|
19
|
Raap M, Antonopoulos W, Dämmrich M,
Christgen H, Steinmann D, Länger F, Lehmann U, Kreipe H and
Christgen M: High frequency of lobular breast cancer in distant
metastases to the orbit. Cancer Med. 4:104–111. 2015. View Article : Google Scholar :
|
|
20
|
Hou X, Wang L, Zhang L, Pan X and Zhao W:
Ubiquitin-specific protease 4 promotes TNF-α-induced apoptosis by
deubiquitination of RIP1 in head and neck squamous cell carcinoma.
FEBS Lett. 587:311–316. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Uras IZ, List T and Nijman SM:
Ubiquitin-specific protease 4 inhibits mono-ubiquitination of the
master growth factor signaling kinase PDK1. PLoS One. 7:e310032012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Luna-Vargas MP, Faesen AC, van Dijk WJ,
Rape M, Fish A and Sixma TK: Ubiquitin-specific protease 4 is
inhibited by its ubiquitin-like domain. EMBO Rep. 12:365–372. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Frederick A, Rolfe M and Chiu MI: The
human UNP locus at 3p21.31 encodes two tissue-selective,
cytoplasmic isoforms with deubiquitinating activity that have
reduced expression in small cell lung carcinoma cell lines.
Oncogene. 16:153–165. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao B, Schlesiger C, Masucci MG and
Lindsten K: The ubiquitin specific protease 4 (USP4) is a new
player in the Wnt signalling pathway. J Cell Mol Med. 13:1886–1895.
2009. View Article : Google Scholar
|
|
25
|
Fredersdorf S, Burns J, Milne AM, Packham
G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, et
al: High level expression of p27(kip1) and cyclin D1 in some human
breast cancer cells: Inverse correlation between the expression of
p27(kip1) and degree of malignancy in human breast and colorectal
cancers. Proc Natl Acad Sci USA. 94:6380–6385. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Miller LD, Smeds J, George J, Vega VB,
Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, et al: An
expression signature for p53 status in human breast cancer predicts
mutation status, transcriptional effects, and patient survival.
Proc Natl Acad Sci USA. 102:13550–13555. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mills GB, Lu Y, Fang X, Wang H, Eder A,
Mao M, Swaby R, Cheng KW, Stokoe D, Siminovitch K, et al: The role
of genetic abnormalities of PTEN and the phosphatidylinositol
3-kinase pathway in breast and ovarian tumorigenesis, prognosis,
and therapy. Semin Oncol. 28(Suppl 16): 125–141. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu Y, Wang Y, Ma G, Wang Q and Wei G:
CUL4A is overexpressed in human pituitary adenomas and regulates
pituitary tumor cell proliferation. J Neurooncol. 116:625–632.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Santhanam AN, Baker AR, Hegamyer G,
Kirschmann DA and Colburn NH: Pdcd4 repression of lysyl oxidase
inhibits hypoxia-induced breast cancer cell invasion. Oncogene.
29:3921–3932. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fischer N, Göke F, Splittstösser V,
Lankat-Buttgereit B, Müller SC and Ellinger J: Expression of
programmed cell death protein 4 (PDCD4) and miR-21 in urothelial
carcinoma. Biochem Biophys Res Commun. 417:29–34. 2012. View Article : Google Scholar
|
|
31
|
Allgayer H: Pdcd4, a colon cancer
prognostic that is regulated by a microRNA. Crit Rev Oncol Hematol.
73:185–191. 2010. View Article : Google Scholar
|
